Back to top

biotechnology: Archive

Shaun Pruitt

3 Cheap Stocks to Buy for Growth & Value

From their current levels, it would be no surprise if Direct Digital (DRCT), Vaalco Energy (EGY), and Grifols' (GRFS) stock moved much higher in 2024.

EGYPositive Net Change GRFSPositive Net Change DRCTPositive Net Change

Zacks Equity Research

Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study

Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.

PBYIPositive Net Change ADMAPositive Net Change ACADPositive Net Change IPHAPositive Net Change

Zacks Equity Research

Best Momentum Stocks to Buy for January 4th

IMGN and GTLB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2024.

IMGNPositive Net Change GTLBPositive Net Change

Zacks Equity Research

Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More

Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.

NVSPositive Net Change BMYNegative Net Change CORTNegative Net Change AGIOPositive Net Change VYGRPositive Net Change

Zacks Equity Research

Ultragenyx (RARE) Posts Update From AS Study of GTX-102

Ultragenyx (RARE) completes enrollment in the phase I/II study of GTX-102 for the treatment of pediatric patients with AS. Top-line data from the study is expected in the first half of 2024.

PBYIPositive Net Change RAREPositive Net Change ADMAPositive Net Change ACADPositive Net Change

Zacks Equity Research

New Strong Buy Stocks for January 4th

IMGN, GTLB, FNWD, BL and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2024.

IMGNPositive Net Change TMHCPositive Net Change BLPositive Net Change FNWDPositive Net Change GTLBPositive Net Change

Zacks Equity Research

Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation

Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.

BMYNegative Net Change MRKPositive Net Change MRTXPositive Net Change TRDAPositive Net Change

Zacks Equity Research

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis

Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.

NVSPositive Net Change DVAXNegative Net Change VYGRPositive Net Change TRDAPositive Net Change

Zacks Equity Research

Best Momentum Stocks to Buy for January 3rd

SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.

REGNNegative Net Change SRPTPositive Net Change WINGPositive Net Change

Zacks Equity Research

Anavex (AVXL) Falls 35% on Mixed Rett Syndrome Study Results

Anavex (AVXL) falls 35% on mixed results from the mid to late-stage study of 30 mg ANAVEX2-73 for the treatment of pediatric Rett Syndrome patients aged 5-17 years.

PBYIPositive Net Change ADMAPositive Net Change ACADPositive Net Change AVXLNegative Net Change

Zacks Equity Research

Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study

Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.

PBYIPositive Net Change ADMAPositive Net Change XENEPositive Net Change

Zacks Equity Research

MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why

MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.

SNYPositive Net Change JNJPositive Net Change CTMXPositive Net Change MGTXNegative Net Change

Zacks Equity Research

Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why

Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.

VRTXNegative Net Change EDITPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.

PBYIPositive Net Change ADMAPositive Net Change ACADPositive Net Change AXSMPositive Net Change

Zacks Equity Research

Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals

Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.

BMYNegative Net Change CYTKPositive Net Change PBYIPositive Net Change ADMAPositive Net Change

Ekta Bagri

Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data

Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.

BMYNegative Net Change AMGNNegative Net Change CYTKPositive Net Change